SCCS Preliminary Opinion on Alpha-Arbutin and Beta-Arbutin
Alpha-arbutin and Beta-arbutin are used in cosmetic with antioxidant, bleaching and skin conditioning functions. Following concerns raised during discussion within the Working Group on Cosmetic Products and consequent call for data on these ingredients, the SCCS assessed the safety of Alpha-arbutin and Beta-arbutin in cosmetic products.

ALPHA-ARBUTIN AND BETA-ARBUTIN

Alpha-arbutin and Beta-arbutin (optical isomer) are similar cosmetic ingredients. In cosmetics and personal care products, these ingredients can be used as antioxidants, bleaching and skin conditioning agents. Currently, neither Alpha-arbutin nor Beta-arbutin are regulated under the EU Regulation (EC) Nº 1223/2009 on cosmetic products.

In 2015, the European Commission’s Scientific Committee on Consumer Safety (SCCS) assessed the safety of Alpha-arbutin and Beta-arbutin and published two opinions. The SCCS concluded that the use of Alpha-arbutin up to a concentration of 2% in face creams and 0.5% in body lotions was safe for consumers. Beta-arbutin was considered safe for consumers when used up to a concentration of 7% in face creams and provided that the contamination of hydroquinone in the cosmetic formulations remained below 1 ppm.

The SCCS opinions did not evaluate the potential combined use of hydroquinone releasing substances in cosmetic products.

Discussions within the Working Group on Cosmetic Products raised concerns on hydroquinone content, its release and regarding the aggregate exposure from cosmetic products containing Alpha-arbutin and/or Beta-arbutin. Consequently, a call for data took place and interested parties were asked to provide relevant data/information related to the stability of these ingredients, their dermal absorption, the hydroquinone release rate (including biotransformation) and the aggregate exposure.

NEW SCCS PRELIMINARY OPINION

Last March, the SCCS released its preliminary opinion on the safety of Alpha-arbutin and Beta-arbutin in cosmetic products.

Based on the data provided and relevant information available in the scientific literature, the SCCS stated that it “cannot conclude on the safety of alpha-arbutin when used in face creams up to a maximum concentration of 2% and in body lotions up to a maximum concentration of 0.5%”.

Regarding the use of Beta-arbutin, no information was provided during the call for data and the information available in the scientific literature was insufficient to conclude on the safety of this ingredient.

The Committee considers that lacking data on degradation/metabolism of Alpha-arbutin and Beta-arbutin, exposed to the skin microbiome/enzymes and the release of hydroquinone and its final fate are essential for the safety assessment. Consequently, the SCCS could not recommend a safe concentration for Alpha-arbutin or Beta-arbutin.

The SCCS preliminary opinion is open for comments until 27 May 2022.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on the safety of alpha-arbutin and beta-arbutin in cosmetic products. SCCS/1642/22. 2022.

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »